实用肝脏病杂志Issue(1)：59-62,4.DOI:10.3969/j.issn.1672-5069.2015.01.015
索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察
Efficacy of transcatheter arterial chemoembolization combined with sorafenib in treatment of patients with advanced hepatocellular carcinoma
摘要
Abstract
Objective To observe the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with targeted therapy for advanced hepatocellular carcinoma. Methods From Jan. 2008,to Dec. 2012,60 cases of advanced hepatocellular carcinoma received TACE,among them,37 cases were treated with so-rafenib after TACE,at a dose of 400 mg,twice a day (the dosage was adjusted according to the side effect). Ab-dominal CT scans were regularly performed and treatment efficacy was evaluated according to the modified RE-CIST. The side effect of sorafenib was recorded,so was the liver function before and after TACE. Results In 37 patients received combined treatment (TACE plus sorafenib) and 23 patients received TACE alone,the median overall survival time were (13±0.98) months and (5±0.62) months,respectively (P=0.001),the time to progression were (7.5±1.21) months and (5±0.62) months,respectively (P=0.001),and at the end of followed-up,the disease control rate were 48.6% and 17.4% in the two groups,respectively (P<0.01);The multivariate analysis showed that the risk factors for death were without combination of sorafenib and antiviral therapy,and the presence of portal vein tumor thrombus. The main side effect of sorafenib was hand-foot skin reaction. Conclusion TACE combined with sorafenib has prolonged time to disease progression and overall survival time in patients with advanced hepa-tocellular carcinoma with relatively good safety.关键词
肝细胞癌/肝动脉化疗栓塞术/索拉非尼/预后Key words
Hepatocellular carcinoma/Transcatheter arterial chemoembolization/Sorafenib/Prognosis引用本文复制引用
周学士,任雷,彭蕾,叶阳群,朱晓黎,冯婷婷,赵卫峰..索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察[J].实用肝脏病杂志,2015,(1):59-62,4.基金项目
江苏省自然科学基金资助项目 （）
